Full paper/Mémoire

Synthesis, antibacterial and antifungal activities of new chiral 5-alkyl-3-(1′-benzenesulfonylpyrrolidin-2′-yl)-4,5-dihydro-1,2,4-oxadiazin-6-ones

Najeh Tka, Nafâa Jegham, Béchir Ben Hassine *

Laboratoire de synthèse organique asymétrique et catalyse homogène (01 UR 1201), département de chimie, faculté des sciences de Monastir, université de Monastir, avenue de l'Environnement, 5019 Monastir, Tunisia

ARTICLE INFO

ABSTRACT

Chiral α-bromoacid chlorides can be easily prepared from amino acids. Their condensation with new 1-benzenesulfonylpyrrolidin-2-carboxamidoxime derived from proline lead to the corresponding *O*-(bromoacyl) amidoximes. The latter afforded new chiral 5-alkyl-3-(1′-benzènesulfonylpyrrolidin-2′-yl)-4,5-dihydro-1,2,4oxadiazin-6-ones in good chemical yields via intramolecular cyclization in the presence of one equivalent of NaH. These new compounds were evaluated for their antibacterial and antifungal activities using micro-dilution tests against some strains of bacteria and fungi. Our compounds showed an excellent antibacterial activity, which is better than the drug levofloxacin.

© 2009 Académie des sciences. Published by Elsevier Masson SAS. All rights reserved.

RÉSUMÉ

Des chlorures de α-bromoacides chiraux préparés facilement au départ d'acides aminés sont condensés avec le 1-benzènesulfonylpyrrolidin-2-carboxamidoxime dérivant de la proline et conduisent aux *O*-(bromoacyl) amidoximes correspondantes. Ces derniers composés conduisent aux nouvelles 5-alkyl-3-(1′-benzènesulfonylpyrrolidin-2′-yl)-4,5-dihydro-1,2,4-oxadiazin-6-ones chirales avec de bons rendements chimiques via une cyclisation intramoléculaire en présence d'un équivalent de NaH. Ces nouveaux produits ont été évalués pour leurs activités antibactérienne et antifongique en utilisant des tests de microdilution contre quelques souches de bactéries et de champignons. L'un de nos produits a montré une excellente activité antibactérienne meilleure que celle du médicament lévofloxacin.

© 2009 Académie des sciences. Publié par Elsevier Masson SAS. Tous droits réservés.

1. Introduction

Oxadiazinones are quite important biologically-active compounds which have gained more interest thanks to their utility as central nervous system stimulants [1,2] and as oxidase B (MAO-B) inhibitor [3]. As far as we know, no works reporting the antibacterial or antifungal activities of this class of heterocycles have been reported.

The high synthetic value of oxadiazinones has been demonstrated specially in Diels–Alder cycloaddition [4,5] and Favorski ring contraction [6]. Recently, fluorinated oxadiazinones have been proposed as a rare example of low molecular weight (LMW) hydrogelators [7].

On the other hand, the synthesis of optically-active oxadiazinones has recently attracted considerable interest in the asymmetric organic synthesis. Optically-active 1,3,4-oxadiazin-2-ones have been successfully investigated by Hitchcock et al. and Vaughn and Hitchcock [8,9] as chiral auxiliaries in the aldol reaction. Moreover, these compounds have been utilised by

---

* Corresponding author.
E-mail address: bechirbenhassine@yahoo.fr (B. Ben Hassine).

Husson et al. as chiral auxiliaries to perform diastereoselective alkylations [10].

Among oxadiazinones, 1,2,4-oxadiazin-6-ones are not very broadly explored and little is known about these compounds which were prepared only once by Hussein et al. [11]. Hussein et al.'s method was not general and gave 1,2,4-oxadiazin-6-ones with moderate yields ranging from 12 to 73% and with no indication of the product's optical purity. Therefore, there is further scope to explore more efficient synthetic methods. Herein, chemically speaking, we report a simple and practical method to achieve the synthesis of new optically pure 5-alkyl-3-(1'-benzenesulfonylpyrrolidin-2'-yl)-4,5-dihydro-1,2,4-oxadiazin-6-ones by the condensation of chiral 1-benzenesulfonylpyrrolidin-2-carboxamidoxime with chiral 2-(S)-2-bromoacid chlorides, followed by cyclization in the presence of one equivalent of sodium hydride. Some tests have been conducted in order to evaluate the antibacterial and antifungal activities of our new 1,2,4-oxadiazin-6-ones.

2. Results and discussion

2.1. Chemistry

The synthetic route to the target compounds 4a–f is outlined in Scheme 1. We have successfully converted commercially available (L)-proline to the corresponding optically pure (2S)-1-benzenesulfonylpyrrolidine-2-carbonitrile 1 [12]. The treatment of this compound with hydroxylamine hydrochloride and two equivalents of triethylamine overnight at room temperature led to the corresponding chiral (2S)-1-benzenesulfonylpyrrolidine-2-carboxamidoxime 2. The condensation of amidoxime 2 with different α-bromoacid chlorides, easily prepared from the corresponding α-aminoacids following a known procedure [13], gave the chiral (O-bromoacyl) (2S)-1-benzenesulfonylpyrrolidine-2-carboxamidoximes 3a–f with chemical yields ranging from 79 to 87%. The final step of this sequence is the intramolecular cyclization of 3a–f in the presence of one equivalent of NaH affording the corresponding 5-alkyl-3-(1'-benzenesulfonylpyrrolidin-2'-yl)-4,5-dihydro-1,2,4-oxadiazin-6-ones 4a–f with good chemical yields and excellent diastereomeric excesses.

The addition reaction of amidoxime to the activated carboxylic acid derivatives has always been described as an easy method for the synthesis of 1,2,4-oxadiazoles [14,15]. As part of our work, directed towards the synthesis of new heterocyclic compounds from amino acids [16,17], we investigate chiral new (2S)-1-benzenesulfonylpyrrolidine-2-carboxamidoxime to cyclise with α-bromoacid chlorides yielding new 1,2,4-oxadiazin-6-ones.

The synthesis of the amidoxime group, mostly involve the preparation of the cyano group, followed by the conversion into an amidoxime group. During this study, we describe the first synthesis of chiral (2S)-1-benzenesulfonylpyrrolidine-2-carboxamidoxime 2. This compound was easy prepared by treatment of (2S)-1-benzenesulfonylpyrrolidine-2-carbonitrile 1 with a hydroxylamine alkaline solution. However, unfortunately, the treatment of α-aminonitriles derived from other amino acids did not provide the corresponding amidoxime with good yields even after heating and prolonging the reaction time.

Work on condensation of amidoximes with acid chlorides has been described before. It is well known that acid chloride reacts with the O-part of the amidoxime [18,19]. The desired esterification products 3a–f were afforded with use of one equivalent of α-bromoacid chloride and 1.2 equivalent of triethylamine. Reaction was performed in an ice bath with short reaction times (45–60 min). In the event of longer reaction times, the reaction leads to a complex mixture.

Finally, the intermediates 3a–f undergo an intermolecular cyclization in the presence of one equivalent of NaH to yield compounds 4a–f within 3 h at −25 °C with good yields. Only one equivalent of NaH has been used in order to avoid the racemisation of the initial stereocenter of the proline by a possible elimination of the proton. We have found that compounds 4a–f were formed without a significant racemization of the asymmetric carbon 5 of the oxadiazinone ring. This result is proved by NMR and by HPLC studies.

According to ^1H NMR spectra of compound 4f prepared from optically pure (2'S)-1-benzenesulfonylpyrrolidine-2'-carboxamidoxime 2 and (D,L) valine, the signal relative to the proton linked to the asymmetric carbon of oxadiazinone ring resonates in different positions for each pair of diasteromers. As shown in Fig. 1, the signal of the C*-H proton of the mixture of the two diastereomers (2'S,5R) and (2'S,5S) 4f appeared as two doublets. A first doublet at 3.95 ppm ($J = 5.7$ Hz) corresponding to the diastereomer (2'S,5S) and a second doublet at 3.99 ppm ($J = 5.1$ Hz)

Scheme 1. Synthesis of (2'S, 5R), 5-alkyl-3-(1'-benzenesulfonyl-pyrrolidin-2'-yl)-4,5-dihydro-1,2,4-oxadiazin-6-ones 4a–f. Reaction conditions: (i) NH₂OH.HCl/Et₃N/CHCl₃; (ii) 2-(S)-2-bromo-acid chlorides/Et₃N/CH₂Cl₂, 0 °C ; (iii) NaH/THF, 3 h, −25 °C.

Fig. 1. The signal of the C*-H proton of **(2′S, 5R), (2′S, 5S) 4f** and **(2′S, 5R) 4b** 5-isopropyl-3-(1′-benzenesulfonylpyrrolidin-2′-yl)-4,5-dihydro-1,2,4oxadiazin-6-ones.

corresponding to the diastereomer (2′S,5R). However, the signal of the C*-H proton of the single diastereomer (2′S,5R) **4b** prepared from optically-pure(2′S)-1-benzene-sulfonylpyrrolidine-2'-carboxamidoxime **2** and (L)-valine, appeared as one doublet at 3.99 ppm (J = 4.2 Hz) showing the high diastereoselectivity of the intramolecular cyclization (Fig. 1). In the same way, ^{1}H NMR spectra of compounds **4a**, **c–e** indicated the absence of peaks expected from racemisation.

The optical purity of 1,2,4-oxadiazin-6-ones **4a–e** was confirmed by HPLC. According to the HPLC studies, compounds **4a–e** are single isomers, and no peaks corresponding to other diastereomers were detected.

Finally, based on ^{1}H NMR and HPLC, we can conclude that the nucleophelic intermolecular substitution of bromine by the amino group affording the oxadiazinone ring has occurred in a typical SN_2 manner.

2.2. Biological activities

The synthesized compounds were tested at concentration ranging from 1 to 0.0018 mg mL^{-1} for antibacterial activity against bacterial strains. The strains of microorganisms employed were *Staphylococcus aureus* ATCC 25923, *Escherichia coli* ATCC 25922, *Klepsiella pneumonie* (clinically isolated) and *Enterococcus faecalis* ATCC 29212. The same compounds were also tested to assess their activity against fungi. The yeasts were *Candida glabrata* ATCC 90030, *C. albicans* ATCC 90028, *C. kreusei* ATCC 6258 and *C. parapsilosis* ATCC 22019.

Antibacterial activities of synthesized 1,2,4-oxadiazin-6-ones **4a–f** were studied along with an antibacterial drug named levofloxacin. The obtained minimum inhibitory concentrations (MIC) values of the tested compounds and standard are shown in Table 1. The results revealed that all compounds showed superior activity than levofloxacin. Reported compounds **4a–f** were found to be very effective at low concentrations, in some cases, the value of minimum inhibitory concentrations (MIC) of our compounds was 10 times lower than levofloxacin. Compound **4c** shows a good antibacterial activity against *E. faecalis* at a concentration of 0.12 mg mL^{-1}. Compounds **4e** against *S. aureus* and **4b** against *E. coli* exhibit a very significant antibacterial activity at a very low concentration, respectively, 0.06 and 0.03 mg mL^{-1}.

Table 1 shows also the antifungal activities of the synthesized 1,2,4-oxadiazin-6-ones **4a–f** in comparison with the antifungal amphotericin B. Based on the obtained

Table 1
Antibacterial and antifungal activities of 1,2,4-oxadiazin-6-ones **4a–f** (**MIC, mg mL^{-1}**).

Bacteria	MIC 4a	MIC 4b	MIC 4c	MIC 4d	MIC 4e	MIC 4f	Amphotericin B	Levofloxacin
K. pneumonie (clinical isolated)	0.06	0.25	0.25	0.12	0.12	0.25	nd	0.3
S. aureus ATCC 27950	0.25	0.12	0.25	0.25	0.06	0.25	nd	0.61
E. faecalis ATCC 29212	0.25	0.25	0.12	0.25	0.25	0.5	nd	1.22
E. coli ATCC 25922	0.25	0.03	0.06	0.25	0.25	0.25	nd	0.3
Yeasts								
C. parapsilosis ATCC 22019 5 45	0.25	0.25	0.25	0.25	0.25	0.25	0.05	nd
C. kreusei ATCC 6258 2.5 45	0.25	0.12	0.12	0.25	0.25	0.25	0.05	nd
C. albicans ATCC 90028	0.12	0.25	0.25	0.25	0.25	0.12	0.05	nd
C. glabrata ATCC 90030	0.25	0.25	0.25	0.12	0.03	0.5	0.05	nd

Levofloxacin: controlled antibiotic; amphotericin B: controlled antifungal. MIC: Minimum Inhibitory Concentrations, values given as mg mL^{-1}; nd: not determined.

values, the synthesized compounds showed moderate antifungal activities with MIC values ranging from 0.03 to 0.25 mg mL^{-1}. In all cases, the minimum inhibitory concentrations of the active compound are higher than the standard used antibiotic, except for compound **4e** against *C. glabrata* which was found to show a good antifungal activity at concentration (0.03 mg mL^{-1}) lower than amphotericin B (0.05 mg mL^{-1}).

It should be pointed out that this evaluation of the antibacterial and antifungal activities of 1,2,4-oxadiazin-6-ones was performed for the first time during this study.

3. Conclusion

In summary, we have synthesized novel biologically important 5-alkyl-3-(1′-benzenesulfonylpyrrolidin-2′-yl)-4,5-dihydro-1,2,4-oxadiazin-6-ones **4a–f** using chiral 2-(S)-1-benzenesulfonylpyrrolidin-2-carboxamidoxime and 2-(S)-2-bromoacid chlorides, both derived from inexpensive and readily available amino acids. The synthetic method has been developed for the first time during this work giving **4a–f** in high chemical yields and occurring without a racemisation as shown by the ^{1}H NMR and HPLC. The reported compounds were screened for their antibacterial and antifungal activities against a spectrum of microbial organisms. These studies proved that all compounds **4a–f** showed excellent antibacterial activities, much better than levofloxacin. As for compound **4e** against *C. glabrata*, it showed a beneficial antifungal activity at a minimum concentration (0.03 mg mL^{-1}). The test dealing with other biological activities of these new products is under investigation in our laboratory.

4. Experimental section

4.1. Chemistry

TLC was performed on Merck 60F-254 silica gel plates (layer thickness 0.25 mm). Column chromatography was performed on silica gel (70e230 mesh) using ethylacetate and cyclohexane mixture. CH_2Cl_2 was distilled over CaH_2 whereas THF was distilled over sodium. Melting points were determined on an electrothermal 9002 apparatus and are uncorrected. NMR spectra were recorded on AC-300 Bruker apparatus (^{1}H at 300 MHz and ^{13}C at 75 MHz). All chemical shifts are reported as δ values (ppm) relative to internal tetramethylsilane. IR spectra were recorded on FTS-6000 BIO-RAD apparatus. Elemental analyses were carried out by the Service of Microanalysis of the "Institut national de recherche et d'analyse physicochimique de Tunis". HPLC analyses were conducted on a heptane/isopropanol system with a UV detector at 254 nm, using a chirobiotic V column (250 × 46 mm) and a 0.6 mL/min flow rate.

4.1.1. General procedure for the preparation of 5-alkyl-3-(1′-yl)-4,5-dihydro-1,2,4-oxadiazin-6-ones

A mixture of (2S),2-alkyl-2-bromoacid (5 mmol), SOCl$_2$ (20 mmol) and three drops of dry DMF in anhydrous

dichloromethane was stirred overnight at room temperature under N$_2$. After the removal of the SOCl$_2$ excess under vacuum, the residue was dissolved in dry dichloromethane and added slowly to a cold solution of (2S)-1-bzenesulfonylpyrrolidin-2-carboxamidoxime (5 mmol) and 1.2 equivalent of triethylamine (6 mmol) in dry dichloromethane at (0 °C). The reaction mixture was stirred for 60 min in an ice bath, and then 20 mL of saturated ammonium chloride solution was added. After separation, the aqueous layer was extracted with chloroform (3 × 50 mL). The chloroformic combined extracts were dried over MgSO$_4$, filtered and concentrated in *vacuo* and the residue obtained was purified by column chromatography on silica gel (40% ethylacetate: 60% cyclohexane) to give (O-bromoacyl) (2S)-1-benzenesulfonylpyrrolidin-2-carboxamidoxime **3a–f**.

4.1.2. (2S)-N-phenylsulfonylpyrrolidin-2-carbonitrile 1

Yield = 89 %; mp = 99–101 °C; [α]$_D$ −1040; (CHCl$_3$, *c* = 0.5); IR (cm^{-1}): ν_{CN} = 2236 (CN); ^{1}H NMR (300 MHz, CDCl$_3$) : δ 2.02–2.19 (m, 4H), 3.33 (m, 2H), 4.58 (dd, 1H, *J* = 6.9 Hz, *J* = 2.7 Hz), 7.53–7.88 (m, 5H); ^{13}C NMR (75 MHz, CDCl$_3$): δ 24.73, 31.97, 47.58, 48.66, 118.03 (CN), 127.55, 129.42, 133.59, 137.29, MS/EI *m/z* = 236 (M$^{+·}$). Anal. Calcd for C$_{11}$H$_{12}$N$_2$O$_2$S,236.29: C 55.91, H 5.12, N 11.86 . Found: C 56.13, H 4.99, N 11.75.

4.1.3. (2S)-N-phenylsulfonylpyrrolidin-2-carboxamidoxime 2

Yield = 94 %; mp = 54–56 °C; [α]$_D$ −112; (CHCl$_3$, *c* = 0.5); ^{1}H NMR (300 MHz, CDCl$_3$) : δ 1.62–1.78 (m, 2H), 1.86–1.95 (m, 1H), 2.12–2.19 (m, 1H), 3.16–3.24 (m, 1H), 3.55–3.69 (m, 1H), 4.13 (dd, 1H, *J* = 6.7 Hz, *J* = 3.1 Hz), 5.10 (l.b, 2H; NH2); 7.54–7.88 (m, 5H); ^{13}C NMR (75 MHz, CDCl$_3$): δ 24.56, 30.23, 49.76, 59.35, 127.87, 129.41, 133.38, 135.94,153.93, MS/EI *m/z* = 269 (M$^{+·}$). Anal. Calcd for C$_{11}$H$_{15}$N$_3$O$_3$S,269.32: C 49.06, H 5.61, N 15.60. Found: C 49.13, H 5.69, N 15.65.

4.1.4. O-2-bromopropanoyle-1-benzenesulfonylpyrrolidin-2′-carboxamidoxime 3a

Yield = 84 %; mp: 129–131 °C; [α]$_D$ = −16.3, (CHCl$_3$, *c* = 0.16); IR (cm^{-1}): $\nu_{C=O}$ = 1752; $\nu_{C=N}$ = 1605; ^{1}H NMR (300 MHz, CDCl$_3$): δ 1.09 (d, 3H, *J* = 6.9 Hz), 1.71 (m, 2H), 1.99 (m, 1H), 2.21 (m, 1H), 3.19 (m, 1H); 3.71 (m, 1H); 3.98 (q, 1H, *J* = 7.1 Hz); 4.33 (dd, 1H, *J* = 8.2 Hz, *J* = 3.9 Hz); 5.71 (s.l, NH), 7.65 (m, 3H); 7.91 (d, 2H, *J* = 8.1 Hz); ^{13}C NMR (75 MHz, CDCl$_3$), δ; 19.91, 23.76, 31.54, 50.14, 53.45, 59.45, 128.48, 129.65, 134.16, 136.15, 160.18, 166.98.

4.1.5. O-2′-bromo-3′-méthylbutanoyle-1-benzenesulfonylpyrrolidin-2-carboxamidoxime 3b

Yield = 86%; mp: 140–142 °C; [α]$_D$ = −14.2, (CHCl$_3$, *c* = 0.16); ^{1} IR (cm^{-1}); $\nu_{C=O}$ = 1761; $\nu_{C=N}$ = 1610; H NMR (300 MHz, CDCl$_3$): δ 1.09 (d, 3H, *J* = 6.5 Hz), 1.16 (d, 3H, *J* = 7.3 Hz), 1.55 (m, 1H), 1.67 (m, 1H), 1.84 (m, 1H), 2.21 (m, 2H), 3.14 (m, 1H); 3.59 (m, 1H); 4.15 (d, 1H,*J* = 4.3 Hz); 4.31 (dd, 1H, *J* = 7.9 Hz, *J* = 4.1 Hz); 5.84 (s.l, NH); 7.63 (m, 3H); 7.84 (d, 2H, *J* = 8.1 Hz); ^{13}C NMR (75 MHz, CDCl$_3$), δ; 20.23, 20.59, 24.95, 31.92, 32.85, 50.42, 53.68, 59.10, 128.36, 129.93, 134.11, 135.50, 160.38, 166.77.

4.1.6. O-2′-bromo-4′-méthylpentanoyle-1-benzenesulfonylpyrrolidin-2-carboxamidoxime 3c

Yield = 81%; mp:146–148 °C; $[\alpha]_D$ = −12.1, (CHCl$_3$, c = 0.16); IR (cm^{-1}); $\nu_{C=O}$ = 1750; $\nu_{C=N}$ = 1604; ^{1}H NMR (300 MHz, CDCl$_3$): δ 1.08 (d, 6H, J = 5.6 Hz), 1.51 (m, 3H), 1.74 (m, 2H), 2.28 (m, 1H); 2.39 (m, 1H); 3.18 (m, 1H); 3.88 (m, 1H), 4.16 (dd, 1H J = 7.5 Hz, J = 6.2 Hz), 4.32 (dd, 1H, J = 7.9 Hz, J = 3.1 Hz); 5.71 (s.l, NH) 7.71 (m, 3H); 7.81 (d, 2H, J = 8.1 Hz); ^{13}C NMR (75 MHz, CDCl$_3$), δ 21.18, 23.84, 25.21, 26.02, 30.54, 33.54, 50.48, 52.21, 60.44, 128.64, 129.98, 134.04, 135.61, 161.12, 166.81.

4.1.7. O-2′-bromo-3′-méthylpentanoyle-1-benzenesulfonylpyrrolidin-2-carboxamidoxime 3d

Yield = 85%; mp:132–134 °C; $[\alpha]_D$ = −17.8, (CHCl$_3$, c = 0.16); ^{1}H NMR (300 MHz, CDCl$_3$): δ 0.88 (t, 3H, J = 4.2 Hz), 0.98 (d, 3H, J = 7.1 Hz), 1.27 (m, 1H), 1.61 (m, 1H), 1.68 (m, 2H), 1.79 (m, 1H), 2.03 (m, 1H); 2.16 (m, 1H); 3.11 (m, 1H); 3.54 (m, 1H), 4.17 (d, 1H, J = 4.1 Hz); 4.23 (dd, 1H, J = 7.9 Hz, J = 3.2 Hz); 5.66 (s.l, NH) 7.58 (m, 3H); 7.80 (d, 2H, J = 8.1 Hz); ^{13}C NMR (75 MHz, CDCl$_3$), δ 11.07, 16.72, 24.94, 26.71, 31.82, 38.87, 50.41, 52.32, 59.21, 128.33, 129.89, 134.06, 135.57, 160.00, 166.87.

4.1.8. O-2′-bromo-3′-phénylpropanoyle-1-benzenesulfonylpyrrolidin-2-carboxamidoxime 3e

Yield = 79%; mp:154–156 °C; $[\alpha]_D$ = −21.6, (CHCl$_3$, c = 0.16); IR (cm^{-1}): $\nu_{C=O}$ = 1751; $\nu_{C=N}$ = 1611; ^{1}H NMR (300 MHz, CDCl$_3$): δ 1.51 (m, 1H), 1.65 (m, 1H), 1.82 (m, 1H), 2.15 (m, 1H), 3.12 (m, 2H), 3.33 (m, 1H), 3.58 (m, 1H); 4.13 (m, 1H); 4.49 (m, 1H); 5.16 (s.l, NH),7.21 (m, 5H); 7.52 (m, 3H); 7.82 (m, 2H, J = 8.1 Hz); ^{13}C NMR (75 MHz, CDCl$_3$), δ 24.89, 31.72, 41.67, 50.38, 57.07, 59.22, 127.80, 128.31, 129.09, 129.14, 134.01, 135.64, 136.24, 159.70, 166.82.

4.1.9. O-2′-bromo-3′-méthylbutanoyle-1-benzenesulfonylpyrrolidin-2-carboxamidoxime 3f

Yield = 87%; ^{1}H NMR (300 MHz, CDCl$_3$): δ 1.04 (m, 6H), 1.62 (m, 1H), 1.83 (m, 2H), 2.19 (m, 2H), 3.08 (m, 1H); 3.66 (m, 1H); 4.11, 4.16 (d, J = 5.6 Hz, d, J = 5.2 Hz, 1H); 4.29 (m, 1H); 5.86 (s, 2H, NH2),7.58 (m, 3H); 7.84 (d, 2H, J = 8.1 Hz); ^{13}C NMR (75 MHz, CDCl$_3$), δ 20.25 (20.33), 20.84, 24.52, 31.45 (31.76), 32.24 (32.37), 50.83, 52.57, 60.56 (60.88), 128.89, 129.62, 134.81, 135.58, 160.76, 166.15 (166.23).

After purification, the products **3a–f** were dissolved in dry THF and added slowly to a solution of 1 equivalent of NaH in dry THF cooled to −25 °C. The reaction mixture was stirred for 3 h. After warming to room temperature, 10 mL of saturated ammonium chloride solution and 50 mL of chloroform were added. After separation, the aqueous layer was extracted with chloroform (3 × 50 mL). The chloroformic combined extracts were dried over MgSO$_4$, filtered and concentrated in vacuo and the residue obtained was purified by column chromatography on silica gel (20% ethylacetate: 80 cyclohexane) to give the 5-alkyl-3-(1′-benzenesulfonylpyrrolidin-2′-yl)-4,5-dihydro-1,2,4-oxadiazin-6-ones, which was recrystallized from (20% ethylacetate: 80% hexane).

4.1.10. (2′S, 5R)-5-methyl-3-(1′-benzenesulfonylpyrrolidin-2′-yl)-4,5-dihydro-1,2,4-oxadiazin-6-one 4a

Yield = 91 %; mp:112–114 °C; $[\alpha]_D$ = −6.0, (CHCl$_3$, c = 0.16); d.e > 99 % [HPLC analysis using a chirobiotic V column 4.6 mm × 250 mm under the following conditions: heptane/isopropanol (95/5) as mobile phase, rt, λ (254 nm; flow rate = 0.6 mL/min. Retention time: 22.12 min]; IR (cm^{-1}): ν_{NH} = 3254; $\nu_{C=O}$ = 1750; $\nu_{C=N}$ = 1600; ^{1}H NMR (300 MHz, CDCl$_3$): δ 1.17 (d, 3H, J = 7.1 Hz), 1.64 (m, 2H), 1.88 (m, 1H), 2.15 (m, 1H), 3.17 (m, 1H); 3.59 (m, 1H); 3.95 (q, 1H, J = 7.2 Hz); 4.27 (dd, 1H, J = 8.1 Hz, J = 3.6 Hz); 7.59 (m, 3H); 7.84 (d, 2H, J = 8.1 Hz), 8.88 (s.l, NH); ^{13}C NMR (75 MHz, CDCl$_3$), δ 17.82, 24.56, 30.23, 49.76, 59.35, 79.87, 127.87, 129.41, 133.38, 135.94, 150.25, 166.48. Anal. Calcd for C$_{14}$H$_{17}$N$_3$O$_4$S, 323.37: C, 52.00, H, 5.30, N, 12.99. Found: C, 52.06, H, 5.37, N, 13.03.

4.1.11. (2′S, 5R)-5-isopropyl-3-(1′-benzenesulfonylpyrrolidin-2′-yl)-4,5-dihydro1,2,4-oxadiazin-6-one 4b

Yield = 93%; mp:125–127 °C; $[\alpha]_D$ = −16.2, (CHCl$_3$, c = 0.16); d.e > 99% [HPLC analysis using a chirobiotic V column 4.6 mm × 250 mm under the following conditions: heptane/isopropanol (95/5) as mobile phase, rt, λ (254 nm, flow rate = 0.6 mL/min. Retention time: 20.44 min]; ^{1}H NMR (300 MHz, CDCl$_3$): δ 1.07 (d, 3H, J = 6.7 Hz), 1.13 (d, 3H, J = 7.1 Hz), 1.68 (m, 2H), 1.93 (m, 1H), 2.38 (m, 2H), 3.22 (m, 1H); 3.57 (m, 1H); 3.99 (d, 1H, J = 4.2 Hz); 4.27 (dd, 1H, J = 7.8 Hz, J = 4.3 Hz); 7.65 (m, 3H); 7.85 (d, 2H, J = 8.1 Hz), 8.89 (s.l, NH); ^{13}C NMR (75 MHz, CDCl$_3$), δ 17.51, 18.82, 24.51, 27.43, 29.44, 49.82, 58.58, 80.78, 127.88, 129.61, 133.80, 135.40, 150.81, 166.09. Anal. Calcd for C$_{16}$H$_{21}$N$_3$O$_4$S,351.43: C, 54.69, H, 6.02, N, 11.96. Found: C, 54.74, H, 6.09, N, 12.03.

4.1.12. (2′S, 5R)-5-isobutyl-3-(1′-benzenesulfonylpyrrolidin-2′-yl)-4,5-dihydro-1,2,4-oxadiazin-6-one 4c

Yield = 90%; mp: 107–109 °C; $[\alpha]_D$ = −22.8, (CHCl$_3$, c = 0.16); d.e > 99 % [HPLC analysis using a chirobiotic V column 4.6 mm × 250 mm under the following conditions: heptane/isopropanol (95/5) as mobile phase, rt, λ (254 nm, flow rate = 0.6 mL/min. Retention time: 25.09 min]; IR (cm^{-1}): ν_{NH} = 3256; $\nu_{C=O}$ = 1754; $\nu_{C=N}$ = 1607; ^{1}H NMR (300 MHz, CDCl$_3$): δ 0.93 (d, 6H, J = 5.8 Hz), 1.48 (m, 3H), 1.67 (m, 2H), 2.15 (m, 1H); 2.33 (m, 1H); 3.14 (m, 1H); 3.46 (m, 1H), 4.04 (dd, 1H J = 7.7 Hz, J = 6.0 Hz), 4.25 (dd, 1H, J = 7.9 Hz, J = 3.2 Hz); 7.63 (m, 3H); 7.83 (d, 2H, J = 8.1 Hz), 8.78 (s.l, NH); ^{13}C NMR (75 MHz, CDCl$_3$), δ 18.28, 19.84, 24.31, 25.02, 29.66, 33.45, 51.08, 59.15, 80.44, 128.83, 130.25, 133.84, 135.61, 151.15, 166.77.

4.1.13. (2′S, 5R)-5-Sec-butyl-3-(1′-benzenesulfonylpyrrolidin-2′-yl)-4,5-dihydro-1,2,4-oxadiazin-6-one 4d

Yield = 92%; mp:102–104 °C; $[\alpha]_D$ = −25.7, (CHCl$_3$, c = 0.16); d.e > 99% [HPLC analysis using a chirobiotic V column 4.6 mm × 250 mm under the following conditions: heptane/isopropanol (95/5) as mobile phase, rt, λ (254 nm, flow rate = 0.6 mL/min. Retention time: 26.03 min]; IR (cm^{-1}): ν_{NH} = 3252; $\nu_{C=O}$ = 1749; $\nu_{C=N}$ = 1596; ^{1}H NMR (300 MHz, CDCl$_3$): δ 0.86 (t, 3H, J = 4.8 Hz), 0.96 (d, 3H,

J = 6.9 Hz), 1.38 (m, 1H), 1.57 (m, 3H), 1.86 (m, 1H), 2.12 (m, 1H); 2.28 (m, 1H); 3.16 (m, 1H); 3.50 (m, 1H), 4.00 (d, 1H, J = 4.2 Hz); 4.21 (dd, 1H, J = 8.1 Hz, J = 3.4 Hz); 7.58 (m, 3H); 7.80 (d, 2H, J = 8.1 Hz), 8.75 (s.l, NH); ^{13}C NMR (75 MHz, CDCl$_3$), δ 12.08, 14.43, 24.89, 26.02, 29.46, 34.33, 50.16, 58.95, 79.41, 128.23, 129.95, 134.14, 135.81, 151.06, 166.80. Anal. Calcd for C$_{17}$H$_{23}$N$_3$O$_4$S, 365.45: C, 55.87, H, 6.34, N, 11.50. Found: C, 55.92, H, 6.40, N, 11.55.

4.1.14. (2′S, 5R)-5-benzyl-3-(1′-benzenesulfonylpyrrolidin-2′-yl)-4,5-dihydro-1,2,4-oxadiazin-6-one 4e

Yield = 77%;   mp:120–122 °C;   [α]$_D$ = −31.6, (CHCl$_3$, c = 0.16); d.e = 97% [HPLC analysis using a chirobiotic V column 4.6 mm × 250 mm under the following conditions: heptane/isopropanol (95/5) as mobile phase, rt, λ (254 nm, flow rate = 0.6 mL/min. Retention time: 28.59 min]; IR (cm^{-1}): ν_{NH} = 3250; $\nu_{C=O}$ = 1753; $\nu_{C=N}$ = 1601; ^{1}H NMR (300 MHz, CDCl$_3$): δ 1.64 (m, 2H), 1.92 (m, 1H), 2.30 (m, 1H), 3.19 (m, 2H), 3.34 (m, 1H), 3.56 (m, 1H); 4.25 (m, 1H); 4.37 (m, 1H); 7.32 (m, 5H); 7.59 (m, 3H), 7.75 (m, 2H, J = 8.1 Hz), 8.84 (s.l, NH); ^{13}C NMR (75 MHz, CDCl$_3$), δ 24.83, 29.30, 34.64, 50.17, 58.92, 78.52, 127.21, 128.24, 128.84, 130.01, 134.16, 135.71, 136.75, 151.37, 166.40. Anal. Calcd for C$_{20}$H$_{21}$N$_3$O$_4$S, 399.47: C, 60.14, H, 5.30, N, 10.52. Found: C, 60.18, H, 5.34, N, 10.58.

4.1.15. (2′S, 5R) and (2′S, 5S)-5-isopropyl-3-(1′-benzenesulfonylpyrrolidin-2′-yl)-4,5-dihydro-1,2,4-oxadiazin-6-one 4f

Yield = 89%; two diastereomers (2′S,5R) and (2′S,5S) [HPLC analysis using a chirobiotic V column 4.6 mm × 250 mm under the following conditions: heptane/isopropanol (95/5) as mobile phase, rt, λ (254 nm, flow rate = 0.6 mL/min. Retention times: 20.44 min and 23.89 min]; ^{1}H NMR (300 MHz, CDCl$_3$): δ 1.07 (m, 6H), 1.72 (m, 2H), 1.93 (m, 1H), 2.36 (m, 2H), 3.23 (m, 1H); 3.56 (m, 1H); 3.95, 3.99 (d, J = 5.7 Hz, d, J = 5.1 Hz, 1H); 4.28 (m, 1H); 7.66 (m, 3H); 7.87 (d, 2H, J = 8.1 Hz), 8.87 (s.l, NH); ^{13}C NMR (75 MHz, CDCl$_3$), δ 17.25 (17.50), 18.84, 24.52, 27.45 (27.76), 29.24 (29.37), 49.83, 58.57, 80.56 (80.88), 127.89, 129.62, 133.81, 135.38, 150.76, 166.05 (166.23).

4.2. Micro-well dilution assays

Minimum inhibitory concentration (MIC) values were determined by a micro-titre plate dilution method described by Sahin et al. [20]. The inoculum of the bacteria and yeasts were prepared from 12 h broth cultures and suspensions were adjusted to 0.5 McFarland standard turbidity. The synthesized compounds **4a–e** were first dissolved in 10% DMSO and then diluted to be tested. In brief, the 96-well plates were prepared by dispensing into each well 100 μL of nutrient broth and 5 μL of the inoculum. A 200 μL stock solution of the compound initially prepared at the concentration of 1 mg mL^{-1} was added into the first well. Then, 100 μL from their serial dilutions was transferred into nine consecutive wells. The last well containing 100 μL of nutrient broth without compound and 5 μL of the inoculum on each strip was used as negative control.

The plate was covered with a sterile plate sealer and then incubated for 18 h at 37 °C. The MIC was defined as the lowest concentration of the compound **4a–e** to inhibit the growth of microorganisms, after incubation. The results were expressed in milligram per milliliter.

Each test was carried out in triplicate. The microorganisms tested in this study were provided from European Hospital of George-Pompidou (HEGP) (France).

References

[1] D.L. Trepanier, J.N. Eble, G.H. Harris, J. Med. Chem. 11 (1968) 357.
[2] D.L. Trepanier, J.N. Harris, Chem. Abstr. 70 (1969) 78026c.
[3] J. Wouters, F. Ooms, S. Jegham, J.S. Koenig, P. George, F. Durant, Eur. J. Med. Chem. 32 (1997) 721.
[4] A. Padwa, P. Eisenbarth, Tetrahedron 41 (1985) 283.
[5] F. Roussi, B. Martine, A. Chiaroni, C. Lriche, H.P. Husson, Tetrahedron Lett. 40 (1999) 3727.
[6] A. Allen, J.P. Anselme, Tetrahedron Lett. 37 (1996) 5039.
[7] A.P. Piccionello, A. Pace, S. Buscemi, N. Vivona, G. Giorgi, Tetrahedron Lett. 50 (2009) 1472.
[8] S.R. Hitchcock, D.M. Casper, J.R. Vaughn, J.R. Finefield, G.M. Ference, J.M. Esken, J. Org. Chem. 69 (2004) 714.
[9] J.F. Vaughn, S.R. Hitchcock, Tetrahedron Asymmetry 15 (2004) 3449.
[10] F. Roussi, M. Bonin, A. Chiaroni, L. Micouin, C. Riche, H.P. Husson, Tetrahedron Lett. 39 (1998) 8081.
[11] A.Q. Hussein, M.M. El-Abadelah, W.S. Sabri, J. Heterocycl. Chem. 21 (1984) 455.
[12] N. Tka, J. Kraïem, Y. Kacem, A. Hajri, B. Ben Hassine, C. R. Chim. 12 (2009) 1066.
[13] M. Larcheveque, Y. Petit, Bull. Soc. Chim. Fr. 1 (1989) 130.
[14] C.K. Sams, J. Lau, Tetrahedron Lett. 40 (1999) 9359.
[15] G.B. Liang, D.D. Feng, Tetrahedron Lett. 37 (1996) 6627.
[16] Y. Kacem, J. Kraiem, E. Kerkeni, A. Bouraoui, B. Ben, Hassine, Eur. J. Pharm. Sci. 16 (2002) 221.
[17] A. Ould Aliyenne, J.E. Khiari, J. Kraiem, Y. Kacem, B. Ben, Hassine, Tetrahedron Lett. 47 (2006) 6405.
[18] K.D. Rice, J.M. Nuss, Bioorg. Med. Chem. Lett. 11 (2001) 753.
[19] L. Oresma, H. Kotikoski, M. Haukka, O. Oksala, E. Pohjala, H. Vapaatalo, P. Vainiotalo, P. Aulaskari, Bioorg. Med. Chem. Lett. 16 (2006) 2144.
[20] F. Sahin, M. Gulluce, D. Daferera, A. Soken, M. Sokmen, M. Polissiou, Food Control 15 (2004) 549.